Spinal Cord Injury Investor Symposium: Inteligex's CEO on stem cells that are designed to account for regional identity differences within the spinal cord, and also engineering a proliferation factor

blonca9
Jun 27, 2024
1 min read

Paul Bradshaw explains how Inteligex's "ReStaRT Cells" are designed with a regional identity, and the rationale for engineering them to express the ChABC and GDNF genes to boost the odds of survival and proliferation.

Recent Posts

See All

CREATE Medicines' platform allows it to program CARs into multiple immune cell types inside the body, and is redosable. While this includes CAR-T, they believe that "in vivo is more than T-cells."

The leaders of London based LabGenius Therapeutics discuss a recent ESMO IO poster for their Nectin-4 x CD3 T-cell engager, and a new expanded collaboration with Sanofi on antibody optimization

Bay Area based Medra, which is building a robotics platform that is capable of doing fully automated lab work for drug discovery and then analyzing and optimizing it, announced a $52M series A today

Spinal Cord Injury Investor Symposium: Inteligex's CEO on stem cells that are designed to account for regional identity differences within the spinal cord, and also engineering a proliferation factor

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight